Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Reloxaliase in Enteric Hyperoxaluria (URIROX-2)
2018-000921-29Phase 3Completed
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Jun 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in absorptive hyperoxaluria and hyperoxaluria comparing Reloxaliase with Placebo (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started Jun 2019; status: completed.
02
Drugs
reloxaliase
03
Conditions
absorptive hyperoxaluriahyperoxaluria
Beyond the preview
Go deeper on 2018-000921-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000921-29.